TEV-50717: Clinical Trials

1 trial of TEV-50717, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 completed. 1 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 21Completed 1
Phase 31Completed 1

Follow TEV-50717: new trials by email Literature Review of TEV-50717 trials Research Report on TEV-50717

Trials (filtered) newest first · largest first

All 1 trial

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Alternatives for Reducing Tics in Tourette Syndrome (TS): A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Tourette Syndrome in Children and Adolescents
TEV-50717, Placebo - Tourette Syndrome
Phase 2 / Phase 3CompletedTeva Branded Pharmaceutical Products R&D, Inc.1192018-02-052021-11-09

Conditions studied

Tourette Syndrome (1)

Sponsors

Teva Branded Pharmaceutical Products R&D, Inc. (1)

Countries

Canada (1)  ·  Denmark (1)  ·  Russia (1)  ·  Serbia (1)  ·  Spain (1)  ·  United States (1)

Results publications

PMID 34609495

NIH funding

2016 (1)